Eylea vs Avastin – Comparing Two Treatments for Wet AMD

Wet age-related macular degeneration (AMD) is a major cause of severe vision loss in older adults. For patients who require anti-VEGF treatment, comparing Eylea vs Avastin can help clarify differences in dosing, cost, regulatory status, and treatment considerations that may influence the choice of therapy.

Both medications target vascular endothelial growth factor (VEGF), helping reduce abnormal blood vessel growth and fluid leakage in the retina. Eylea was developed specifically for retinal diseases, while Avastin was originally approved for cancer treatment and is widely used off-label in ophthalmology.

This article compares their mechanisms of action, clinical effectiveness, safety profiles, treatment frequency, and cost to provide a clearer picture of how the two options differ in the management of wet AMD.

Key Takeaways

• Both treatments improve vision, but Eylea often allows for longer intervals between injections (8-12 weeks versus Avastin’s 4 weeks), which may be more convenient for patients.
• Common side effects for both include mild eye pain and temporary vision changes. Eylea may carry a higher risk of inflammation, while Avastin has slightly elevated risks of systemic complications like stroke.
•  Eylea suits patients who prefer fewer injections and seek an FDA-approved option. Avastin appeals to those seeking affordable treatment who can tolerate more frequent injections.
• To ensure optimal outcomes, the choice between Eylea and Avastin should be based on individual patient needs, financial situations, and ophthalmologists’ recommendations.
•  Both treatments are effective but differ in cost, dosing, and risk profiles. Personalized care is crucial for preserving long-term vision and ensuring patient satisfaction.

About: Doctor Medica is your trusted supplier of top-quality dermal fillers, viscosupplements, and a range of medical and aesthetic products for your practice. We offer authentic products from leading brands at the lowest prices. Contact Doctor Medica today!

Recommended products

Considering a Purchase?

Sign in to Explore Options.

Sign In

Eylea vs Avastin: Mechanisms of Action

Both Eylea (aflibercept) and Avastin (bevacizumab) work by inhibiting VEGF, the protein behind abnormal blood vessel growth and fluid leakage in the retina. Despite their shared target, each drug takes a slightly different approach:

• Eylea is a fusion protein crafted specifically for eye health, binding both VEGF-A and VEGF-B with high affinity. This dual action can lead to a longer-lasting effect and, for some patients, fewer injections over time.
  
• Avastin, initially developed to combat certain types of cancer, focuses on VEGF-A alone. Though originally intended for oncology, it’s widely used “off-label” for wet AMD and has proven effective at reducing unwanted fluid buildup and bleeding.
  

In essence, both medications curb the effects of VEGF. However, Eylea’s tailored design often provides a more prolonged suppression, making it a convenient choice for individuals aiming to limit frequent injections.

Treatment frequency also has practical implications for clinics that manage patients requiring ongoing anti-VEGF therapy. For licensed practices that buy Eylea wholesale, maintaining a dependable supply from a reputable source can help support continuity of treatment while providing confidence in product authenticity and appropriate handling.

Efficacy in Clinical Trials

Clinical evidence comparing Eylea vs Avastin shows that both treatments can improve vision in retinal disease, although differences in treatment intervals and patient response may influence which option is preferred. Multiple studies show they can improve vision, though they differ in durability, treatment intervals, and patient suitability.

On Eylea (Aflibercept)

• VIEW 1 and VIEW 2 Studies: An integrated analysis of the two-year results from the VIEW 1 and VIEW 2 studies demonstrated that patients receiving Eylea (2 mg every 8 weeks) gained an average of +7.6 letters from baseline at week 96, compared to +8.4 letters at week 52.[1] These patients received an average of 11.2 injections over two years.
• Comparison with Lucentis: A clinical trial directly compared Eylea and Lucentis (ranibizumab) for treating wet AMD and found them to be similarly effective. Another trial focusing on DME found that Eylea was more likely to improve vision than Lucentis in patients with more severe vision loss.[2][3]
• Weaning off Treatment: A retrospective study analyzing patients who were weaned off wet AMD therapy found that patients in the Eylea arm were three times more likely to be weaned off treatment compared to those receiving Avastin (43% vs. 15%).[4] This benefit persisted through two years (52% vs. 27%), suggesting a potentially longer-lasting effect with Eylea.

On Avastin (Bevacizumab)

• CATT Trial: The Comparison of AMD Treatments Trials (CATT) found that Avastin and Lucentis provided comparable visual acuity improvements at one and two years. This landmark study supported the use of Avastin as a cost-effective alternative to Lucentis for wet AMD.[5]
• Outperformance in DME: An NIH-funded clinical trial comparing Eylea, Avastin, and Lucentis for DME found that Eylea outperformed Avastin in patients with 20/50 or worse vision at the start of the trial. After two years, visual acuity improved substantially in all three groups, but Eylea showed a clear advantage over Avastin in this specific patient population.[6]
• Injection Frequency: Patients in the Avastin (bevacizumab) group received more injections on average (8.7 ± 0.3) compared with the Eylea arm (7.2 ± 0.3)

Safety Profiles and Side Effects

Safety is an important consideration when comparing Eylea and Avastin. Both treatments can cause temporary ocular reactions, but their individual risk profiles and regulatory histories differ. Patients concerned about the long-term side effects of Eylea injections should discuss both ocular and systemic risks with their ophthalmologist as part of ongoing treatment planning.

Common Side Effects (Both Drugs)

• Mild eye pain or irritation
• Temporary vision changes
• Increased intraocular pressure

Specific Risks

• Eylea: May carry a slightly higher risk of inflammation inside the eye, yet it tends to have fewer systemic side effects overall. If you have concerns about Eylea’s possible long-term side effects, be sure to discuss them with your doctor.
  Avastin: Used “off-label” for eye conditions, it can pose a marginally higher risk of systemic complications (e.g., stroke, heart attack) in susceptible patients.

Cost Considerations and Accessibility

When choosing between Eylea and Avastin, cost often plays a pivotal role, as their prices can vary dramatically.

• Eylea: Known for its specialized formulation and official FDA approval for eye diseases, Eylea typically comes with a higher price tag. Even if covered by insurance, out-of-pocket costs can still add up.
• Avastin: Originally developed for cancer treatment, Avastin is repurposed for wet AMD, making it significantly more affordable. Though it’s used “off-label,” its cost-effectiveness has led many clinics to adopt it as a first-line option.

As a result, patients without comprehensive insurance coverage often favor Avastin, while those seeking fewer total visits or who have comprehensive insurance may lean toward Eylea, even at a higher price.

Patient Selection and Personalized Treatment

The choice between Eylea and Avastin often comes down to each patient’s specific needs and guidance from their ophthalmologist. Both drugs have distinct advantages, so personalized care is vital to achieving the best possible outcomes.

• Eylea suits patients who benefit from fewer injections—such as those with limited mobility—or those who have not responded well to Avastin. It’s also preferred by individuals wanting an FDA-approved treatment specifically designed for wet AMD.
• Avastin is a practical choice for those seeking a cost-effective option or who have previously used off-label treatments without complications. It may also fit individuals who can tolerate more frequent injections without significant inconvenience.

By considering factors like medical history, lifestyle, and financial situation, ophthalmologists can recommend a treatment plan that preserves long-term vision and ensures patient satisfaction.

Conclusion

When comparing Eylea vs Avastin, both treatments can play an important role in managing wet AMD, but they differ in cost, dosing schedules, regulatory status, and specific treatment considerations. Eylea provides extended intervals between injections and has full FDA approval for AMD, while Avastin offers a more budget-friendly option with similar efficacy. 

Ultimately, the best choice depends on individual medical needs, financial considerations, and close collaboration between patients and their healthcare providers.

FAQs

1. Is Eylea better than Avastin for wet AMD?

Both Eylea and Avastin effectively treat wet AMD. Eylea may offer longer-lasting effects with fewer injections, while Avastin is a more affordable off-label option.

2. How do Eylea and Avastin differ in their mechanisms?

Eylea is a targeted fusion protein that binds multiple VEGF forms, offering more prolonged suppression. Avastin blocks VEGF-A and is adapted from cancer treatment.

3. Which treatment has more side effects: Eylea or Avastin?

Both have similar local side effects. Avastin may pose a slightly higher risk of systemic events like stroke due to its off-label use.

4. How do costs compare between Eylea and Avastin?

Eylea is significantly more expensive but FDA-approved for AMD. Avastin is more affordable but used off-label. Insurance coverage may vary.

Citations

[1] Ohr, Matthew, and Peter K Kaiser. “Aflibercept in wet age-related macular degeneration: a perspective review.” Therapeutic advances in chronic disease vol. 3,4 (2012): 153-61. doi:10.1177/2040622312446007

[2] Marshall, Helen. “Eylea (Aflibercept): Side Effects, Alternatives, Dosage, and More.” Medical News Today, medically reviewed by Alex Nguyen, 19 Dec. 2025, www.medicalnewstoday.com/articles/eylea.

[3] Cai, Sophie, and Neil M Bressler. “Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T.” Current opinion in ophthalmology vol. 28,6 (2017): 636-643. doi:10.1097/ICU.0000000000000424

[4] Cao, Xuan et al. “Aflibercept more effectively weans patients with neovascular age-related macular degeneration off therapy compared with bevacizumab.” The Journal of clinical investigation vol. 133,2 e159125. 17 Jan. 2023, doi:10.1172/JCI159125

[5] Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group et al. “Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.” Ophthalmology vol. 119,7 (2012): 1388-98. doi:10.1016/j.ophtha.2012.03.053

[6] Wells, John A et al. “Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.” Ophthalmology vol. 123,6 (2016): 1351-9. doi:10.1016/j.ophtha.2016.02.022